MG-132

製品コードS2619

MG-132化学構造

分子量(MW):475.62

MG132 is a potent cell-permeable proteasome and calpain inhibitor with IC50s of 0.1 and 1.2 μM for the inhibition of proteasome and calpain, respectively.

サイズ 価格(税別)  
JPY 8300.00
JPY 28220.00
JPY 78020.00

Selleckは効果が一番いいである(S,R,S)-(-)-2のコンフィギュレーションを採用しましたので、MG-132プロテアソームの抑制効果はSigmaの同類製品の効果より著しく高くなります

正常には、p21蛋白はユビキチン化で分解されますが、MG-132はプロテアソームの活性を抑制することを通じて、p21蛋白の貯まりを引き起こします。だから、MG-132の抑制効果は強ければ強いほど、p21蛋白の貯まりは多くなってきます。(検査された蛋白:p21  細胞株:HeLa细胞株 処理条件:濃度5μM 処理時間:6h)

文献中の使用例(48)

カスタマーフィードバック(11)

  • Western blot of IκBζ expression in BMDMs treated with DI and stimulated with LPS for 1 h. MG132 or bafilomycin A (BafA) were added 30 min before LPS stimulation.

    Nature, 2018, 556(7702):501-504. MG-132 purchased from Selleck.

    MDA-MB-231 cells were treated with 10 uM MG132 and incubated under normoxia or hypoxia for 4 h. Endogenous interaction between LATS2 and SIAH2 was analysed by immunoprecipitation.

    Nat Cell Biol 2015 17(1), 95-103. MG-132 purchased from Selleck.

  • HeLa cells were transfected with control mimic, RMND5A siRNA or miR-138 mimic. After transfection for 36 h, cells were treated with proteasome inhibitor MG132 (20 uM) or Dimethyl sulfoxide (DMSO) for 8 h. Endogenous Exportin-5 protein and RMND5A protein expression was measured by western blotting.

    Nucleic Acids Res 2014 42(1), 458-74. MG-132 purchased from Selleck.

    HeLa cells were transfected with negative control mimic, miR-138 mimic or RMND5A siRNA. After transfection for 36 h, cells were treated with MG132 (20 uM) or DMSO for 8 h. RMND5A and Exportin-5 protein expression were analyzed by immunocytochemistry. Nuclei were counterstained with DAPI.

    Nucleic Acids Res 2014 42(1), 458-74. MG-132 purchased from Selleck.

  •  

    TFEB induced autophagy dependent ATZ clearance in vitro. MEF transiently co-transfected with either ATZ plus GFP expressing plasmids or ATZ plus TFEB expressing plasmids were incubated with proteasome inhibitor MG132 or with DMSO for 6 h. Upon MG132 treatment, steady state levels of 52 kDa ATZ band increased in both cells transfected with ATZ plus GFP and with ATZ plus TFEB expressing plasmids. Quantification of band intensities showed a 48% reduction of ATZ in cells transfected with ATZ plus TFEB compared to cells transfected with ATZ plus GFP, in the absence of the proteasome inhibitor. In MG132 treated cells, a 61% decrease of ATZ was detected in cells transfected with ATZ plus TFEB compared to cells transfected with ATZ plus GFP.

    EMBO Mol Med 2013 5, 397-412. MG-132 purchased from Selleck.

    JAK1 expression was analyzed in A375 cells expressing scrambled shRNA or shRNF125 (#2) and treated with MG132 (5 uM, 10 hr), and in Lu1205 cells expressing WT RNF125 and treated with MG132.

    Cell Rep 2015 11(9), 1458-73. MG-132 purchased from Selleck.

  • LRB1 and LRB2 regulate phyB protein levels. PhyB protein levels in crude extracts from the wild type (WT) and the indicated mutant backgrounds were assayed by immunoblot analysis with anti-phyB monoclonal antibodies. Anti-PBA1 and anti-histone H3 antibodies were used to confirm equal protein loading. Rc-induced loss of phyB in the wild type is inhibited by 100 uM MG132.

    Plant Physiol 2012 60(1), 118-34. MG-132 purchased from Selleck.

    Representative images for γ-H2AX-stained cells treated with 100 uM FA for 3 h without or with MG132. Fluorescence was measured in at least 50 nuclei in each of three experiments.

    Toxicol Appl Pharmacol 2015 286(2), 135-41. MG-132 purchased from Selleck.

  • GSK-3β phosphorylation at Ser9 is enhanced in NOK-overexpressed stable cell lines. The proteasome inhibitor, MG132, was added in medium of HeLa-HA and HeLa-NOK-HA cells for 12 h and then the p-GSK-3b(Ser9) was assayed by western blotting.

    FEBS Lett 2012 586, 3787–3792. MG-132 purchased from Selleck.

    Nek2A impedes SuFu ubiquitination. HEK293T cells transfected with Nek2A-Myc and Flag-SuFu for 48 h were treated with MG-132 to enrich ubiquitinated proteins, and subsequently subjected to co-immunoprecipitation assay. Precipitated proteins were probed using anti-Ub antibody.

    Int J Oncol, 2017, 50(2):373-380. MG-132 purchased from Selleck.

  • Truncated mouse Period2 (Per2) protein was expressed in NIH3T3 cells, treated by cycloheximide with or without MG132 for 1-4 hours.Per2 was reported to be degraded by the proteasome proteolysis. By adding MG132 (25 μM), a proteasome inhibitor, the degradation of Per2 was dramatically decreased within 4 hours treatment (shown by western blot).

    2012 Dr. Edison DUKE-NUS Graduate Medical School Singapore.. MG-132 purchased from Selleck.

質量管理及び製品安全説明書

Proteasome阻害剤の選択性比較

生物活性

製品説明 MG132 is a potent cell-permeable proteasome and calpain inhibitor with IC50s of 0.1 and 1.2 μM for the inhibition of proteasome and calpain, respectively.
ターゲット
20S proteasome [9]
(Cell-free assay)
100 nM
体外試験

MG-132 displays >1000 times more activity than ZLLal in inhibiting the ZLLL-MCA-degrading activity of 20S proteasome with IC50 of 100 nM versus 110 μM. MG-132 also inhibits calpain with IC50 of 1.2 μM. MG-132 induces neurite outgrowth in PC12 cells at an optimal concentration of 20 nM, displaying 500 times more potency than ZLLal. [1] MG-132 (10 μM) potently inhibits TNF-α-induced NF-κB activation, interleukin-8 (IL-8) gene transcription, and IL-8 protein release in A549 cells by inhibition of proteasome-mediated IκBα degradation. [2] MG-132 treatment potently induces p53-dependent apoptosis in KIM-2 cells by 26S proteasome inhibition. [3] Unlike BzLLLCOCHO or PS-341, MG-132 treatment results in weak inhibition of the chymotrypsinlike (CT-L) and peptidylglutamyl peptide hydrolysing (PGPH) activities of the 26S proteasome, whereas multiple myeloma cells (U266 and OPM-2) are more sensitive to induction of apoptosis by MG-132 than BzLLLCOCHO. [4] MG-132 (1 μM) sensitizes TRAIL-resistant prostate cancer cells by activating the AP-1 family members c-Fos and c-Jun, which, in turn, repress the antiapoptotic molecule c-FLIP(L). [5] MG-132 significantly enhances the ability of inositol hexakisphosphate (IP6) to reduce cellular metabolic activity in both PC3 and DU145 androgen-independent prostate cancer (AIPCa) cell lines. [6]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
LPS-stimulated RAW264.7 cells M1;udGZ2dmO2aX;uJGF{e2G7 MX6yOUDPxE1? M3;Vb2ROW09? Mn3aTY5pcWKrdIOgcol1emmlIH;4bYRmKHC{b3T1Z5Rqd25id3n0bEBKSzVyIH;mJFAvOSEQvF2= MnXKNlQ3QTd2OU[=
HL-60 MoTtR5l1d3SxeHnjJGF{e2G7 NX;LdWJyPDBizszN MlTEOFghcA>? NXrQO2pTTE2VTx?= Mki1TWM2ODxzMDFOwG0> NFj1cZAzPDZ7N{S5Oi=>
SMMC-7721 M1LKcGN6fG:2b4jpZ{BCe3OjeR?= MYe0NEDPxE1? NU[zSVE5PDhiaB?= NXLS[pJsTE2VTx?= Mlr6TWM2OD15LkGg{txO NHW5cGIzPDZ7N{S5Oi=>
A-549 MVvDfZRwfG:6aXOgRZN{[Xl? NVnoRVAzPDBizszN MmfhOFghcA>? M1X6[mROW09? M1XpfWlEPTB:MUCg{txO NUfqTIhnOjR4OUe0PVY>
MCF-7 NVzFZlBmS3m2b4TvfIlkKEG|c3H5 NGXJcHQ1OCEQvF2= M4jxR|Q5KGh? NX3qTFdmTE2VTx?= MUjJR|UxRTdwMzFOwG0> MX6yOFY6PzR7Nh?=
SW-480 Mk[0R5l1d3SxeHnjJGF{e2G7 M{HQTFQxKM7:TR?= MXm0PEBp MVLEUXNQ NEjmRXZKSzVyPUSg{txO NEfFeJkzPDZ7N{S5Oi=>
NCI-H929 NX3kNm1xS3m2b4TvfIlkKEG|c3H5 M4WzWlEh|ryP MnzwO|IhcA>? M3jRbmROW09? NU\BdlNvUUN3ME2wMlE4KM7:TR?= NYLhOnFVOjR4MkWwPFg>
293T Mmq0R5l1d3SxeHnjJGF{e2G7 M37HdVExKM7:TR?= M4nrSlczKGh? M13LZWROW09? NUfST3I1UUN3MEyyJO69VQ>? NFTlVXozPDZ{NUC4PC=>
293T NHjme4dHfW6ldHnvckBCe3OjeR?= Mlv2NVAh|ryP NGXh[|QzPCCq NYH3TJpYTE2VTx?= NIfVZ3pOd2SncnH0[Yx6KGmwZIXj[ZMhcGWjdD3zbI9kcyBi M4fZXVI1PjJ3MEi4
HeLa M122dGtqdmG|ZTDBd5NigQ>? NIm5XoEyOCEQvF2= NXPlVlNoOSCq M3fEWGROW09? MUDJcoR2[2W|IGDBVnAh[2ynYY\h[4Uh[nliaX7obYJqfGmwZzDwdo9{\WG|b33lJIFkfGm4aYT5 NXzGbI5yOjR|MkG4N|M>
MDA-MB-231 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHOPYYyKM7:TR?= MnvFO|IhcA>? NIm0cWpFVVOR NIrlfWRKSzVyPUCuNVgh|ryP MnPXNlQyPTN{ME[=
MCF-7 NYHCR4d1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{T6W|Eh|ryP NGHLbHU4OiCq MVTEUXNQ NGrnNJNKSzVyPUCuNVMh|ryP NIr6eJkzPDF3M{KwOi=>
MCF10A MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2q1UFEh|ryP MXW3NkBp M1nTfmROW09? MWDJR|UxRTBwMkmg{txO M3rEO|I1OTV|MkC2
HEK-293 M2nFUWtqdmG|ZTDBd5NigQ>? MoPTNkBidmRiMkCg{txO NELkSVIzKGh? MXnEUXNQ NFzh[4JKdmirYnn0d{BEcFRvTDDhZ5Rqfmm2eTD3bZRpKEmFNUCgc4YhQSCwTTC= NGLSSVkzOzV2MEe5NC=>
Calu6 NUTLWlhtTnWwY4Tpc44hSXO|YYm= NUP1ZZR6OTBizszN MV:xPEBp MWDEUXNQ NIn6WJNUcWewaX\pZ4FvfGy7IHHjZ5VufWyjdHXzJIZz[XSjeHnuJJBz\WO3coPvdi=> NI[1UJQzOzVyNkS4Oi=>
IFN-gamma-induced RAW264.7 M1\pb2Z2dmO2aX;uJGF{e2G7 NVrFToF7TE2VTx?= NG\pOVJKdmirYnn0d{BvcXS{aXOgc5hq\GVicILv[JVkfGmxbjD3bZRpKEmFNUCgc4YhOC5yN{eg{txO NHKwXGMzOjJ5N{K3Oy=>
IPC227F MnPoR5l1d3SxeHnjJGF{e2G7 MVSxJO69VQ>? MVm0PEBp MoDsSG1UVw>? MmK0TWM2OD1yLkC3O{DPxE1? M4flPFIyQTJ2NUK4
Hepa-1c1c7 M3PHcWZ2dmO2aX;uJGF{e2G7 M4jpdFI2KM7:TR?= MXu2JIg> MWfEUXNQ MXLJcoNz\WG|ZYOgUpJnOiCycn;0[YlvKGyndnXs NVXGTnVROjB|OUK1OFQ>
COS-7 MXHDfZRwfG:6aXOgRZN{[Xl? M1HweVExKM7:TR?= NUDFRpoxTE2VTx?= NF;mTYtKSzVyPEGwJO69VQ>? NFfHRmQyQDB6OEC5Oy=>
HuH-7 M3rzd2N6fG:2b4jpZ{BCe3OjeR?= MmO4NVAh|ryP NWH2XItXTE2VTx?= MXzJR|UxRDFyIN88US=> MoizNVgxQDhyOUe=
OCI-Ly3 MWrGeY5kfGmxbjDBd5NigQ>? M1rXVlExKM7:TdMg MmLPOEBp NWWwUmxVTE2VTx?= M1PUZmlv\HWlZYOgbJVu[W5iSXvhdJBiSmGucHjhJJN1[WKrbHn6ZZRqd25id3n0bEBGSzVyIH;mJFEh|ryP Mn74NVgxOjRzMUO=
A2780 cDDP NWW2[2txSXCxcITvd4l{KEG|c3H5 M2KxdFI1KGh? MUTEUXNQ MmPLTY5lfWOnczDhdI9xfG:|aYOgZpkhcW6qaXLpeIlv\yCSVFXOJIRm\3KjZHH0bY9v NWHs[2pDOTd4OESwNVg>
LPS-stimulated RAW264.7 cells MmH5SpVv[3Srb36gRZN{[Xl? M3TTU2ROW09? MV3Jcohq[mm2czDOSk1s[XCyYVKgSG5CKGKrbnTpcoc> NELTTWYyPzRyN{K3Oy=>
PC12 NFj3V2tHfW6ldHnvckBCe3OjeR?= MkCwNVAxKM7:TdMg NH35UmozPCCq M37Wb2ROW09? NYDVWXM3UW6qaXLpeJMhPi2RSFTBMUBidmRiSELPNk1qdmS3Y3XkJIN6fG:2b4jpZ4l1gQ>? NH\RbY4yPzF3OES1OC=>
PC3 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTvTZVROjBizszN M{LZPFQ5KGh? MX7EUXNQ NFfQPGlKSzVyPUCuOkDPxE1? MY[xOlY5PjV|Nx?=
LP-1 MW\BdI9xfG:|aYOgRZN{[Xl? NFfoV2Q{ODBibl2= M4jKeFI1KGh? M2O5b2ROW09? NGTUbXFKdmS3Y3XzJIFxd3C2b4Ppd{BjgSCrbnPy[YF{cW6pIHPs[YF3\WRiUFHSVEBt\X[nbDDhcoQhemWmdXPpcochVWOuLUGgdJJwfGWrbjDs[ZZmdA>? M2XENVE2QTV6NUi5
ES6 NXK5R5E{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLmb2dKSzVyPUCuNFE{ODZizszN MkPwV2FPT0WU
A101D M2DoRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDFTWM2OD1yLkCzNlc6KM7:TR?= NGrD[VlUSU6JRWK=
OCUB-M M2HjNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTBwMEO3N|ch|ryP M2Pn[nNCVkeHUh?=
LB2518-MEL NWfrV5p1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\vXmRKSzVyPUCuNFM4PiEQvF2= NI[zNmFUSU6JRWK=
SH-4 MlTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTBwMESzNUDPxE1? MV\TRW5ITVJ?
KNS-42 M1HaXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\jd5VKSzVyPUCuNFQ1PDFizszN MYDTRW5ITVJ?
DSH1 MlX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnj4TWM2OD1yLkC1Nlg6KM7:TR?= MUfTRW5ITVJ?
NTERA-S-cl-D1 NGHkd3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnMTWM2OD1yLkC1O|czKM7:TR?= M3WxdnNCVkeHUh?=
D-542MG M3PHUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXRdXBOUUN3ME2wMlA2QTV5IN88US=> MnP2V2FPT0WU
KS-1 M331ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFWyWnZKSzVyPUCuNFY1PThizszN MUnTRW5ITVJ?
BL-41 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1u2SWlEPTB;MD6wOlk1PyEQvF2= MofvV2FPT0WU
LXF-289 NGDXOolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTBwMEewOlYh|ryP MWPTRW5ITVJ?
D-247MG MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXRTWM2OD1yLkC3NlA6KM7:TR?= NHG5XG1USU6JRWK=
MMAC-SF NEXSTm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTBwMEeyOlgh|ryP MmflV2FPT0WU
CP66-MEL NIHTPINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17OfmlEPTB;MD6wO|Uh|ryP NGHw[FBUSU6JRWK=
LB771-HNC M3fnRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUi0NlJIUUN3ME2wMlA5ODN4IN88US=> M4nqWXNCVkeHUh?=
no-10 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PHb2lEPTB;MD6wPFkxQSEQvF2= NYjSRo1VW0GQR1XS
A388 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvTTWM2OD1yLkC5NFY2KM7:TR?= NXvCZ4c{W0GQR1XS
OPM-2 MlLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPhWGFCUUN3ME2wMlExPDd2IN88US=> MkTJV2FPT0WU
OVCAR-4 MnLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnrTWtKSzVyPUCuNVA6OzhizszN M{D6[HNCVkeHUh?=
HOP-62 MmXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;k[JFTUUN3ME2wMlExQTR7IN88US=> NGP0UZZUSU6JRWK=
ML-2 M4nYWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTDSZdVUUN3ME2wMlEyQDB4IN88US=> NIPw[pBUSU6JRWK=
UACC-257 M1ywSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXaOoZKSzVyPUCuNVE6OjdizszN NH7JNItUSU6JRWK=
NEC8 NUnuUHpsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rtdWlEPTB;MD6xNVk6PSEQvF2= NIHWRZRUSU6JRWK=
ONS-76 NVfYcYlCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PW[WlEPTB;MD6xNlk{PSEQvF2= MlzJV2FPT0WU
KE-37 NYHtNpVwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3K3UGlEPTB;MD6xN|I4QCEQvF2= MUXTRW5ITVJ?
HT-144 MlraS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{Hm[mlEPTB;MD6xN|g6PSEQvF2= MXrTRW5ITVJ?
LB2241-RCC NHK0RoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfFTWM2OD1yLkG0NlQ4KM7:TR?= NUf0dnFFW0GQR1XS
TE-5 M13KS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\mPYRKSzVyPUCuNVQzPzhizszN M37zOnNCVkeHUh?=
KINGS-1 M1roRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIj6SYxKSzVyPUCuNVQ4QSEQvF2= MoHpV2FPT0WU
NCI-H69 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDJTWh3UUN3ME2wMlE2OTRzIN88US=> M4nTdXNCVkeHUh?=
CAS-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXL4VHlvUUN3ME2wMlE2PDh{IN88US=> M161RnNCVkeHUh?=
D-263MG NHf0Vm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETqb5NKSzVyPUCuNVYxODZizszN NIfWW|JUSU6JRWK=
A253 Mlj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrZV3ZKSzVyPUCuNVYyOjhizszN Mm[1V2FPT0WU
PF-382 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFKyXoRKSzVyPUCuNVY4ODZizszN NF3nfG5USU6JRWK=
CESS MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFj6foxKSzVyPUCuNVcxPiEQvF2= MXzTRW5ITVJ?
MZ2-MEL NXzzNZQxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWH5SmxRUUN3ME2wMlE4PTV7IN88US=> NInTUGdUSU6JRWK=
HEL NUXvOlB4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rSNmlEPTB;MD6xPFUyPyEQvF2= MXPTRW5ITVJ?
D-392MG MnXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTBwMUmxNVUh|ryP NYfHb3hxW0GQR1XS
SK-LMS-1 M1LHfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHtSGF{UUN3ME2wMlE6OzB|IN88US=> MXfTRW5ITVJ?
GI-ME-N NHPFZ49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTBwMUmzNFYh|ryP Ml:xV2FPT0WU
LB831-BLC MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXf2WpA3UUN3ME2wMlE6OzRizszN NGTNR3dUSU6JRWK=
DU-4475 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnPTWM2OD1yLkG5OlU5KM7:TR?= MXfTRW5ITVJ?
IST-SL1 M1\DUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTBwMkCwPVQh|ryP NWHkR2FYW0GQR1XS
GAK Ml;6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIm3OmtKSzVyPUCuNlA2OzRizszN NX\hcWo{W0GQR1XS
EW-1 NIXpZ2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4ewd2lEPTB;MD6yNVA1PyEQvF2= MV7TRW5ITVJ?
LAMA-84 NWPHTYxMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHq2TmNKSzVyPUCuNlE5PTFizszN MnXqV2FPT0WU
SK-UT-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHFclM1UUN3ME2wMlIzODR7IN88US=> MljDV2FPT0WU
VA-ES-BJ NH3E[5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoWyTWM2OD1yLkKyNlU4KM7:TR?= NWHSRlA3W0GQR1XS
ACN MkfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXu4e4RVUUN3ME2wMlIzPjN6IN88US=> MXvTRW5ITVJ?
SK-PN-DW MmfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnf5TWM2OD1yLkKzNVkh|ryP MU\TRW5ITVJ?
HD-MY-Z NWH1cZRvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DzR2lEPTB;MD6yN|MxOyEQvF2= NF3jc5BUSU6JRWK=
LB373-MEL-D NITLNIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTBwMkSxPVgh|ryP NYnIRZh1W0GQR1XS
COLO-829 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\x[I97UUN3ME2wMlI1OjV5IN88US=> NEDwZYJUSU6JRWK=
ES8 NILtPI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2izW2lEPTB;MD6yOFc3OyEQvF2= NEnUTYRUSU6JRWK=
RXF393 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPufGFKSzVyPUCuNlUxOTVizszN MWnTRW5ITVJ?
TK10 NWfYcFU2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTBwMkW0N|Uh|ryP Mk\HV2FPT0WU
LOUCY NUD2N4NvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFS1XGJKSzVyPUCuNlU1PTZizszN MYrTRW5ITVJ?
MZ7-mel M1noVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rvTmlEPTB;MD6yOlM4PCEQvF2= NXTVcIpqW0GQR1XS
CP67-MEL MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LCc2lEPTB;MD6yOlc{KM7:TR?= MVPTRW5ITVJ?
C2BBe1 Mn;zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTBwMke5NFch|ryP MXjTRW5ITVJ?
K052 NILlRYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTBwMki5PUDPxE1? MYjTRW5ITVJ?
MOLT-16 NFm2NoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DuN2lEPTB;MD6yPVUzPCEQvF2= M1HtNnNCVkeHUh?=
KNS-81-FD M3n3fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTBwM{CzNlMh|ryP M4WxR3NCVkeHUh?=
CMK MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1OwPGlEPTB;MD6zNVEzKM7:TR?= MXXTRW5ITVJ?
LAN-6 M{SyNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nSSGlEPTB;MD6zNVMh|ryP NVXzPWNWW0GQR1XS
KLE Mkn0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\Nb5dKSzVyPUCuN|E{ODZizszN NVLRZlBbW0GQR1XS
NCCIT NGDFbmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDPTWM2OD1yLkOxO|g{KM7:TR?= Ml:wV2FPT0WU
HH M1vLXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoG0TWM2OD1yLkOyPFk4KM7:TR?= NVrNWVl2W0GQR1XS
TE-8 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLnVpJKSzVyPUCuN|QzPzlizszN NGnw[W9USU6JRWK=
GDM-1 M33uS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXG4cmt4UUN3ME2wMlM2OTB2IN88US=> MWPTRW5ITVJ?
NCI-H747 NFrleVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfFOY1NUUN3ME2wMlM4OTB|IN88US=> NYHyc2FTW0GQR1XS
NCI-H1092 NGfaUZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfJUJFZUUN3ME2wMlM5QDR2IN88US=> NHHsTpVUSU6JRWK=
8-MG-BA MoHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXNTWM2OD1yLkO5PFM4KM7:TR?= M{DJSnNCVkeHUh?=
NB17 NWDZdFV5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTBwNEK5O{DPxE1? NUK4bndsW0GQR1XS
LC4-1 NUnvVVFtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWW5O3BHUUN3ME2wMlQ{PjB5IN88US=> MknUV2FPT0WU
TE-1 NYDXeXNST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHBTWM2OD1yLkS1NVE6KM7:TR?= NXjsbG1EW0GQR1XS
KALS-1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\zRWlEPTB;MD60OlU5PCEQvF2= NHf2d3hUSU6JRWK=
CCRF-CEM NGrGd|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTBwNEe2O|Qh|ryP MVTTRW5ITVJ?
OS-RC-2 NXXaN|Q6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjuUXVKSzVyPUCuOFc6PzJizszN MnPxV2FPT0WU
A704 NHrQSlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXqTWM2OD1yLkS4OlkzKM7:TR?= MnPuV2FPT0WU
BB49-HNC MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M324XmlEPTB;MD60PVA6PiEQvF2= MkmxV2FPT0WU
EVSA-T NEjGPIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPxOoxKSzVyPUCuOFk6OTFizszN NIfCbWpUSU6JRWK=
Mo-T Mn\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWr6U4psUUN3ME2wMlUyPzZ{IN88US=> NWDiNpBYW0GQR1XS
MONO-MAC-6 M1Owemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33kRmlEPTB;MD61N|YyOSEQvF2= M120T3NCVkeHUh?=
BB65-RCC M1LCemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;uSGlEPTB;MD61OlgyOSEQvF2= M1\BOnNCVkeHUh?=
NCI-H1882 M164[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\QTWM2OD1yLkW5NFM3KM7:TR?= NXe3NGV6W0GQR1XS
TE-9 M{P2cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HvbGlEPTB;MD62NVA{OyEQvF2= MV3TRW5ITVJ?
NCI-H2126 NEHD[mhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTBwNkK2Olkh|ryP NU[wPWwyW0GQR1XS
SF268 NH:0XpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTBwNkW2OFEh|ryP M3LvRnNCVkeHUh?=
SW872 NGfubm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmWxTWM2OD1yLk[1O|I6KM7:TR?= M{DxXHNCVkeHUh?=
LS-513 NF\FS|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTBwNk[3OVEh|ryP M1OzbXNCVkeHUh?=
NCI-H1355 Ml23S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTBwNki2NVkh|ryP M36zSHNCVkeHUh?=
BL-70 NFewWFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4W0VWlEPTB;MD62PVM5QCEQvF2= MkHKV2FPT0WU
NCI-SNU-5 Ml7VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;Hc3FKSzVyPUCuOlk2PDVizszN M2rIdXNCVkeHUh?=
SNU-C2B M2XTPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvWXGRIUUN3ME2wMlcxPzN7IN88US=> MVTTRW5ITVJ?
GB-1 M1[5UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmOzTWM2OD1yLkeyNVI1KM7:TR?= NYH5RlhRW0GQR1XS
CTB-1 NYHScotKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\lcmlEPTB;MD63O|k2PSEQvF2= NULEcJY2W0GQR1XS
Becker MlvWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPTcXlKSzVyPUCuO|k3OjFizszN NIXXRVFUSU6JRWK=
KM12 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnQeHFWUUN3ME2wMlg2PDZ4IN88US=> M2\x[3NCVkeHUh?=
ES7 NVOwWVh5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2Pk[WlEPTB;MD64PVY2KM7:TR?= Ml\NV2FPT0WU
COLO-684 NE\aO2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\nTWM2OD1yLkmwOlU5KM7:TR?= NXrqPGF5W0GQR1XS
HCC2998 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHUcphKSzVyPUCuPVM5PTRizszN NGK3UnlUSU6JRWK=
TE-10 NWjnUWI2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTBwOU[0N{DPxE1? Mkj2V2FPT0WU
SF126 M1HKXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoL6TWM2OD1yLkm4PVcyKM7:TR?= NEP6O5VUSU6JRWK=
EKVX NXToPG1yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fJb2lEPTB;MT6wN|Q1OiEQvF2= MkSxV2FPT0WU
KARPAS-45 NGTQVVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYf5Z5lkUUN3ME2xMlA1ODF4IN88US=> M4Hy[XNCVkeHUh?=
KGN MlvpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2TRXWlEPTB;MT6wOVA1PSEQvF2= MVnTRW5ITVJ?
ES1 NEnKO4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTFwMEe5NlEh|ryP MonrV2FPT0WU
L-540 NIPxV2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nCZmlEPTB;MT6xNVg{QSEQvF2= NUHDVHR5W0GQR1XS
KURAMOCHI MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTGTWM2OD1zLkGyN|c1KM7:TR?= MUPTRW5ITVJ?
LU-65 NH3kU5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfHVFdKSzVyPUGuNVI4PTNizszN Ml[yV2FPT0WU
MFH-ino MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTSOZZKSzVyPUGuNVc2ODFizszN M37Mb3NCVkeHUh?=
NCI-H23 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIe3VYRKSzVyPUGuNlA1OSEQvF2= M1;ZT3NCVkeHUh?=
IA-LM MmTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXH2V|JxUUN3ME2xMlI1OTF4IN88US=> M1TpOHNCVkeHUh?=
PSN1 M{fRVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPRTWM2OD1zLkK3NFE3KM7:TR?= M1;JNHNCVkeHUh?=
NCI-H719 MkLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTFwMke0NVEh|ryP NF7IOFlUSU6JRWK=
SW684 NFTYcWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTFwMki2OVkh|ryP MkOzV2FPT0WU
HCE-4 MoDuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTFwM{CyNlEh|ryP NYK2SI14W0GQR1XS
EW-16 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33ZbmlEPTB;MT6zNVM1PyEQvF2= NV\hZlAxW0GQR1XS
NCI-H128 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTFwM{W4NVQh|ryP MVfTRW5ITVJ?
HC-1 NYHScYozT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;PeY9OUUN3ME2xMlM5OTdizszN MnnOV2FPT0WU
IST-MES1 MnrsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\vTmlEPTB;MT60NFIxQCEQvF2= NH71N4FUSU6JRWK=
Raji MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\WVGlEPTB;MT60NVg2KM7:TR?= NFLzO|ZUSU6JRWK=
DMS-114 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTFwNES1N|kh|ryP M1jROXNCVkeHUh?=
GI-1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrz[ZBwUUN3ME2xMlQ4OTNzIN88US=> MmHKV2FPT0WU
NCI-H2081 M1;V[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDjbnpFUUN3ME2xMlU2OTl4IN88US=> MUnTRW5ITVJ?
LC-1F M3vpeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITWcZFKSzVyPUGuOVUyQThizszN M{LHWHNCVkeHUh?=
NCI-H2227 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnIcmtsUUN3ME2xMlYyPTZzIN88US=> NGfLN5JUSU6JRWK=
D-502MG Mo\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnCVHh1UUN3ME2xMlY4OjFzIN88US=> M3;0Z3NCVkeHUh?=
NCI-H2141 NIPRSJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPqW3FKSzVyPUGuOlc{OTdizszN MnK3V2FPT0WU
LS-411N M2iwWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7mcmt7UUN3ME2xMlY6QDB5IN88US=> Ml\6V2FPT0WU
SU-DHL-1 Mmi3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoX1TWM2OD1zLkexNlgyKM7:TR?= M3PHNHNCVkeHUh?=
BB30-HNC Mmq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoniTWM2OD1zLkeyOlg2KM7:TR?= MV3TRW5ITVJ?
TE-15 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\MSnNKSzVyPUGuPVI{PzNizszN NXfoVZdNW0GQR1XS
JVM-3 MnPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\YPWlEPTB;MT65N|kxPCEQvF2= MmfVV2FPT0WU
IST-SL2 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHN[GpjUUN3ME2yMlAyOjV{IN88US=> MknEV2FPT0WU
EW-18 NGXjUYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrKUFhKSzVyPUKuNFI{OzdizszN MlfsV2FPT0WU
DJM-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYqzR5czUUN3ME2yMlAzPTV{IN88US=> NXz2[W9pW0GQR1XS
no-11 MnnyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWize3ZwUUN3ME2yMlA{OTB2IN88US=> NHi4PIFUSU6JRWK=
QIMR-WIL MkKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzsWXJKSzVyPUKuNVY4PjJizszN MkDYV2FPT0WU
MC-CAR MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTJwMkK5OUDPxE1? MlnyV2FPT0WU
KM-H2 NWTKN5o6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\XTWM2OD1{LkK5NFQ{KM7:TR?= MWXTRW5ITVJ?
ECC12 NX7GRXg1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XyXmlEPTB;Mj6zO|k1KM7:TR?= M1HaTXNCVkeHUh?=
HCE-T NX:yb|JnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXMV5RKSzVyPUKuOFQ5QDNizszN MWfTRW5ITVJ?
MFM-223 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTJwNUC4O|Eh|ryP NWLWWYx5W0GQR1XS
SW982 NFLCenZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{OyPWlEPTB;Mj61NVQ5KM7:TR?= NYjuW3BJW0GQR1XS
KG-1 M1;Qe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHf1[XdKSzVyPUKuPFg4QTFizszN NYPMb4o5W0GQR1XS
ES4 NEPKRmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTNwME[xNVEh|ryP NXL5U|Z7W0GQR1XS
SCC-3 M2PkSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTNwMUC4OFgh|ryP MlXwV2FPT0WU
RH-1 MkSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTNwM{i3OFgh|ryP M365XnNCVkeHUh?=
NCI-H748 NETMXXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHHU5BYUUN3ME2zMlQ1OjZ4IN88US=> NXXTfIxuW0GQR1XS
HCC2218 NHjhR|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHkb25mUUN3ME2zMlQ3QTN5IN88US=> M1jxUnNCVkeHUh?=
MEG-01 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;sUJJzUUN3ME2zMlU6PjhizszN MnPQV2FPT0WU
NB12 NUnZeY91T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;uSW92UUN3ME2zMlU6QDh6IN88US=> MYrTRW5ITVJ?
SNB75 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTNwNkCxNFMh|ryP NEXodnlUSU6JRWK=
KMS-12-PE NYj6bmVpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfCU2xKSzVyPUOuOlc4OjNizszN Ml:4V2FPT0WU
SKM-1 NHzI[3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13oOGlEPTB;Mz63NVM4PiEQvF2= NFzobFhUSU6JRWK=
COLO-320-HSR NEjub|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPvWVdKSzVyPUOuO|U3OzRizszN NVTERoJNW0GQR1XS
NKM-1 M4rETWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4r3PWlEPTB;Mz63O|M4QCEQvF2= NWTJbHdiW0GQR1XS
TE-6 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XaOGlEPTB;Mz65OFU3OSEQvF2= NIjNPWtUSU6JRWK=
D-336MG NYPNcld3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rhW2lEPTB;ND6wNVE3PiEQvF2= NIfEZlFUSU6JRWK=
NCI-H1650 NH\ieIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjWTWM2OD12LkG1O|k4KM7:TR?= NX[xRWd2W0GQR1XS
ES3 M3;IdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfkTWM2OD12LkOyPFI1KM7:TR?= NFj6[2hUSU6JRWK=
YT MnjKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\OclRKSzVyPUSuN|U1OjRizszN MnjlV2FPT0WU
ES5 M4PVWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTRwNECyOVUh|ryP NUPHOWxDW0GQR1XS
LB647-SCLC NW\4SlBrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjWTWM2OD12LkW2N|A5KM7:TR?= NXTaW25TW0GQR1XS
HAL-01 M{XIWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDZTWM2OD12LkW3NFM1KM7:TR?= MlzYV2FPT0WU
LP-1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTRwN{KzO|Eh|ryP Mm\rV2FPT0WU
BC-1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTVwMEC0OFch|ryP NW\qeXhSW0GQR1XS
EB-3 NWfYc21XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnT3TWM2OD13LkCzNFQyKM7:TR?= NVzSbI93W0GQR1XS
GT3TKB NEDYXW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7hTWM2OD13LkG3OlYzKM7:TR?= MXXTRW5ITVJ?
NCI-H209 NUC3WWI1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTVwMUmzOVIh|ryP MYnTRW5ITVJ?
BT-474 NIP0S|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjaeWNCUUN3ME21MlI{OTB{IN88US=> MUHTRW5ITVJ?
RKO MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfocI5KSzVyPUWuNlM1OjJizszN NEPoNXNUSU6JRWK=
SIMA NX7NclVRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3G2XmlEPTB;NT6zNFc3PSEQvF2= NUPKWJVlW0GQR1XS
RL NELSSHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3:0e2lEPTB;NT6zO|U1OSEQvF2= MVrTRW5ITVJ?
GCIY M37nNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTVwNEeyN|Yh|ryP NFPESolUSU6JRWK=
Calu-6 NFvFfIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfxWotKSzVyPUWuOlIzKM7:TR?= NHXxNIZUSU6JRWK=
ALL-PO M{XCU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfvTWVRUUN3ME21MlY{Pzl3IN88US=> MlfyV2FPT0WU
ARH-77 M1yzTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHiTWM2OD13Lk[3NFg4KM7:TR?= NGK5OWJUSU6JRWK=
A4-Fuk NGjOfFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HR[2lEPTB;Nj6wPFEyQCEQvF2= NYSySWZTW0GQR1XS
NCI-H1581 NXnNbZRkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFS0To1KSzVyPU[uNlM5PDlizszN NWTqNopMW0GQR1XS
HUTU-80 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mli1TWM2OD14LkO2PFk4KM7:TR?= MWHTRW5ITVJ?
TGW MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVy5eolWUUN3ME22MlQ2PTl|IN88US=> Mmr3V2FPT0WU
SK-N-FI MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXVe2xKSzVyPU[uOFU5PTRizszN NGG5eVZUSU6JRWK=
U-266 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7aOYtWUUN3ME22MlUyQTJ4IN88US=> MlXKV2FPT0WU
EM-2 NVPyc|QyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTZwNkewPVkh|ryP MmHoV2FPT0WU
NMC-G1 NVTiSZpUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTZwN{G4PVUh|ryP MWXTRW5ITVJ?
KASUMI-1 NITHWZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkC2TWM2OD14Lki0O|g4KM7:TR?= NHfMdnhUSU6JRWK=
NALM-6 NHW2XZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjhXlNKSzVyPU[uPFY4PTRizszN MX3TRW5ITVJ?
OCI-AML2 M{jiZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3Fe2ZtUUN3ME23MlAxOzJ4IN88US=> M{\WOXNCVkeHUh?=
SHP-77 M1\MWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PsbmlEPTB;Nz6yNlQ{KM7:TR?= MkLrV2FPT0WU
NOMO-1 NF;hcmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYn6fmZJUUN3ME23MlI1OjV2IN88US=> MVnTRW5ITVJ?
SK-N-DZ MkPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\mTWM2OD15LkexNFg6KM7:TR?= M2G0cnNCVkeHUh?=
LB1047-RCC NXPLe3lPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\Gb2dKSzVyPUeuO|IzOzFizszN NFTu[GRUSU6JRWK=
MZ1-PC NYDIWGVJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLKTWM2OD15Lki2OVU5KM7:TR?= NH7BeWNUSU6JRWK=
NB10 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfMUG5KSzVyPUeuPVk2PTZizszN MoHLV2FPT0WU
RL95-2 NE\OZZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRThwMUC4OFIh|ryP NEi3fIZUSU6JRWK=
OMC-1 NHH2cWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37mPWlEPTB;OD61NlE6OSEQvF2= MmD1V2FPT0WU
D-283MED NYjvc|N1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRThwOUG3NVkh|ryP Mkj6V2FPT0WU
MC116 M1fWZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELDUpNKSzVyPUiuPVc6PCEQvF2= MmrRV2FPT0WU
SJSA-1 M{Xx[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PubmlEPTB;OT6wPVA6OSEQvF2= NEn3SWlUSU6JRWK=
JiyoyeP-2003 NHPMV5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTlwMkmzNVch|ryP MUfTRW5ITVJ?
IST-MEL1 NGPyeIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\lb2x{UUN3ME25Mlc1OTl6IN88US=> MYrTRW5ITVJ?
CTV-1 MniyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HS[2lEPTB;MUCuNFk4QSEQvF2= NXy3NJBqW0GQR1XS
NH-12 M{PQNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLrd|BKSzVyPUGwMlI1OzNizszN MonvV2FPT0WU
CA46 M3jUSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVroOVZ3UUN3ME2xNE4{PjFizszN NVrqOplMW0GQR1XS
NCI-SNU-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfCN5lZUUN3ME2xNE41QTZ7IN88US=> MWnTRW5ITVJ?
SCLC-21H MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHYUYVKSzVyPUGwMlY2QTZizszN MY\TRW5ITVJ?
EC-GI-10 M3zNVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHzTWM2OD1zMD63NFMyKM7:TR?= MmXiV2FPT0WU
SR M3zS[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDDfpBKSzVyPUGxMlAyQDVizszN NVHFN2lFW0GQR1XS
NCI-H1648 M2TES2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnz2TWM2OD1zMT6wPVY2KM7:TR?= M{WzXnNCVkeHUh?=
TGBC1TKB MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jFbmlEPTB;MUGuOFExOiEQvF2= NHHnSolUSU6JRWK=
EW-11 MmPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWKzVXRVUUN3ME2xNU42OTh4IN88US=> MnLuV2FPT0WU
SK-MM-2 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX[2RXBvUUN3ME2xNU45ODZzIN88US=> MXjTRW5ITVJ?
NCI-H524 NHzxSJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37zRmlEPTB;MUGuPVgzOiEQvF2= NYjTUplJW0GQR1XS
NOS-1 NHu2OGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\PR2JFUUN3ME2xNk4xOzR3IN88US=> MlPyV2FPT0WU
AM-38 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmC0TWM2OD1zMj61OlM{KM7:TR?= MX;TRW5ITVJ?
A498 M1v6fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3WzWWlEPTB;MUKuO|A3QSEQvF2= MlXoV2FPT0WU
KARPAS-422 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3YTWM2OD1zMj63OFk3KM7:TR?= MmTuV2FPT0WU
LU-139 M2j0UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTF{LkmwNlYh|ryP MWLTRW5ITVJ?
COR-L88 NYj4ZZh2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XCeGlEPTB;MUKuPVM5OiEQvF2= MUXTRW5ITVJ?
K5 MmLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFr1e4hKSzVyPUGyMlk1PjJizszN M4LFbXNCVkeHUh?=
NB13 NYjsfYhZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvvfIdKSzVyPUGyMlk4QDNizszN MoqyV2FPT0WU
MRK-nu-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLtXGJkUUN3ME2xN{4yQTVizszN NIPGUJpUSU6JRWK=
MHH-NB-11 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrSVJplUUN3ME2xN{4zQTB{IN88US=> MXvTRW5ITVJ?
KU812 NWnKO5RGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzuNVg2UUN3ME2xN{43OTJ2IN88US=> M2[5OHNCVkeHUh?=
TE-12 MkPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnGVIZKSzVyPUGzMlY6QTRizszN NFi5bpdUSU6JRWK=
NCI-N87 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTF|LkezOkDPxE1? M17ZdnNCVkeHUh?=
EB2 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVKwXIV4UUN3ME2xN{45PTB3IN88US=> MWjTRW5ITVJ?
DB M{jReWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTaTWM2OD1zMz65PFg2KM7:TR?= MUfTRW5ITVJ?
697 M3PyO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGf0fWZKSzVyPUG0MlQ2OTFizszN M1jKcHNCVkeHUh?=
MSTO-211H MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvQOnpKSzVyPUG0Mlc1PDhizszN NFi2XlRUSU6JRWK=
JVM-2 Ml;YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfNVnpKSzVyPUG0Mlc4OzVizszN M4XDdXNCVkeHUh?=
COLO-824 M3Xwcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\tO2lEPTB;MUSuO|k6PCEQvF2= NWGzbmtYW0GQR1XS
BC-3 MlmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYC1ZmpNUUN3ME2xOU4{QThizszN Moe4V2FPT0WU
BOKU MkOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXPTWM2OD1zNT65OlA5KM7:TR?= NEfse3hUSU6JRWK=
GOTO MmH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTF4Lkm2NVch|ryP MmPwV2FPT0WU
HCC2157 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HLb2lEPTB;MUeuOFc2PSEQvF2= MYLTRW5ITVJ?
LS-1034 MkTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIGwWm5KSzVyPUG3MlY5OThizszN NI\McoNUSU6JRWK=
CAL-148 NXfoZo9XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrDNIdKSzVyPUG3Mlk4QTZizszN M4DaXHNCVkeHUh?=
MOLT-4 MnvNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DjR2lEPTB;MUiuPFIxQCEQvF2= NWXUSm5uW0GQR1XS
Daudi MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXSTWM2OD1zOD65NlMyKM7:TR?= NF\vW3VUSU6JRWK=
J-RT3-T3-5 MlzJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTwTWlbUUN3ME2xPU41ODZ4IN88US=> M3;0WXNCVkeHUh?=
KMOE-2 NITKcVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV25U4tEUUN3ME2xPU43PDh{IN88US=> NGjPUItUSU6JRWK=
HL-60 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Moj2TWM2OD1{MD6xPVY2KM7:TR?= MmjHV2FPT0WU
P31-FUJ MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlGwTWM2OD1{MD60O|U{KM7:TR?= M3rINXNCVkeHUh?=
IM-9 NIn4R49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV:wSWV3UUN3ME2yNE43OjJ2IN88US=> MVHTRW5ITVJ?
HDLM-2 MlnsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTJyLki4NlEh|ryP NFrjZVhUSU6JRWK=
NCI-H1304 M3vZfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTJzLkCzNVEh|ryP NHrDTWlUSU6JRWK=
NCI-H345 M3jFUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGe5WZBKSzVyPUKxMlA3PDNizszN NVfEZ|JFW0GQR1XS
RPMI-6666 MkTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTJzLkO2NFIh|ryP MVvTRW5ITVJ?
GR-ST M3fVbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvUTWM2OD1{MT60NVch|ryP MmfTV2FPT0WU
CHP-126 NH3ocYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXYTWM2OD1{MT62NVgyKM7:TR?= M1HLV3NCVkeHUh?=
EHEB Mnn5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DzNmlEPTB;MkGuOlc{OSEQvF2= NHTFXHpUSU6JRWK=
CPC-N MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoO1TWM2OD1{ND6wNlAyKM7:TR?= NGjLc4VUSU6JRWK=
NB1 M33mTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjmW5RTUUN3ME2yOE43QTN7IN88US=> Ml\SV2FPT0WU
LS-123 NIPSZVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfM[lVKSzVyPUK0MlkxOTJizszN MkHDV2FPT0WU
ST486 NWPqTG0zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;TXmlEPTB;MkWuNVEyOyEQvF2= M13xdHNCVkeHUh?=
NCI-H1963 MlrxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLKbFBKSzVyPUK2MlA3OjNizszN NEnjTJlUSU6JRWK=
U-87-MG MnzSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTJ4Lke2OFQh|ryP NHTTNGpUSU6JRWK=
COR-L279 NIW1fGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYGzdo5DUUN3ME2yOk44QTJ{IN88US=> NFnBVJNUSU6JRWK=
LU-165 M2fWbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYS1N3pYUUN3ME2yPE4xQDZzIN88US=> MWnTRW5ITVJ?
COLO-800 M2Swe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfUTWM2OD1{OD6yPVU3KM7:TR?= NGq1NYZUSU6JRWK=
ETK-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXuT4dsUUN3ME2yPE4{PDR4IN88US=> NGnnWIJUSU6JRWK=
LNCaP-Clone-FGC NVLR[2hRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTJ7LkmyPFEh|ryP NGDZdmdUSU6JRWK=
SIG-M5 NWDpcHRZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXHRopKSzVyPUOwMlc6PTJizszN MWrTRW5ITVJ?
NB6 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTNyLkm1NFMh|ryP M3zzcHNCVkeHUh?=
NCI-H2107 M1fvbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTNzLkKzN|gh|ryP MUTTRW5ITVJ?
SNU-C1 NWLtTVl6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfFTWM2OD1|MT6zNVI3KM7:TR?= Ml3vV2FPT0WU
JAR MnXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\uTWM2OD1|MT6zO|k6KM7:TR?= MXzTRW5ITVJ?
L-363 NXux[2dMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjZTWM2OD1|Mj6yNVQ1KM7:TR?= MorsV2FPT0WU
EW-24 NF;zSYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXuTWM2OD1|Mj6zOFc1KM7:TR?= NGDBV2pUSU6JRWK=
NB69 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTN|Lk[0OVQh|ryP MVLTRW5ITVJ?
EW-13 M2rlXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLaTWM2OD1|Mz64PVY6KM7:TR?= MYDTRW5ITVJ?
Ramos-2G6-4C10 MnnPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LVZWlEPTB;M{SuNlk6OyEQvF2= NEXKPZhUSU6JRWK=
TE-11 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HkVWlEPTB;M{SuOFgzOiEQvF2= NWDyTphWW0GQR1XS
L-428 MofPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEL1W|lKSzVyPUO0Mlc2OzZizszN NY[wb5NCW0GQR1XS
KP-N-YN NVXPbGVtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTN2LkmwOVch|ryP NFvK[nJUSU6JRWK=
CGTH-W-1 MoDMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjDbIJtUUN3ME2zOk46ODR6IN88US=> M2PWNHNCVkeHUh?=
K-562 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV:2cYhQUUN3ME2zO{4xQDZ2IN88US=> MkDQV2FPT0WU
NCI-H1299 NWX2S2tDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljsTWM2OD1|OD6xOlA{KM7:TR?= MYjTRW5ITVJ?
RCC10RGB MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfCNHRKUUN3ME2zPE4zODh|IN88US=> MWTTRW5ITVJ?
NCI-SNU-16 M2Lo[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\zOoxLUUN3ME2zPE42PjV|IN88US=> NUPXbGx6W0GQR1XS
LC-2-ad MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHPTo5wUUN3ME2zPU41OzN5IN88US=> M2nqU3NCVkeHUh?=
MHH-PREB-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjHTWM2OD1|OT63N|g5KM7:TR?= NWDVSZdTW0GQR1XS
NCI-H64 NWHJbolLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PF[2lEPTB;NECuNFk1QCEQvF2= Ml;vV2FPT0WU
LB996-RCC NHPifpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;rTWM2OD12MD64O|E3KM7:TR?= NITBO3ZUSU6JRWK=
DEL NX:3W3VbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\RUldKSzVyPUSxMlQ1ODVizszN MUjTRW5ITVJ?
MLMA NW\SSlJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTRzLke1PVUh|ryP NH73UFFUSU6JRWK=
SBC-1 NX:4R4lVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\PUYlqUUN3ME20Nk4yQDB4IN88US=> M2LZPXNCVkeHUh?=
MPP-89 M{DxZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jVcmlEPTB;NEKuOVg4PSEQvF2= MWfTRW5ITVJ?
MV-4-11 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLaNGZKSzVyPUSyMlkxPjdizszN MXvTRW5ITVJ?
EoL-1- Mnq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7k[5RKSzVyPUS0MlE2PjhizszN Mo\QV2FPT0WU
CW-2 MlHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rIOGlEPTB;NESuPFM1OiEQvF2= MoXyV2FPT0WU
HT NVG4TpRZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEizbFhKSzVyPUS1MlcxODdizszN NVXNWJc5W0GQR1XS
SW954 M4jBXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTR5LkSxNlgh|ryP MX3TRW5ITVJ?
A3-KAW Mn63S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjFTWM2OD12OT64NFYyKM7:TR?= NGSw[XRUSU6JRWK=
TC-YIK Mnv0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTmTWM2OD13MD6wN|Y{KM7:TR?= M3jkV3NCVkeHUh?=
SW962 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fvbmlEPTB;NUSuPFM2PyEQvF2= Mn7lV2FPT0WU
KP-N-RT-BM-1 MkLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPCTWM2OD13Nj62OlM5KM7:TR?= NWnqcoJoW0GQR1XS
NCI-H1395 NI\z[GxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTV6LkixO|Ih|ryP NF[5WmdUSU6JRWK=
RPMI-8402 M3nUUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvuRYhKSzVyPUW4Mlk2OjZizszN NFz1O5JUSU6JRWK=
SCH MmLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTZyLkm2N|gh|ryP NEnLVopUSU6JRWK=
NCI-H2196 M4HrOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjPcWY3UUN3ME22NU4zOzFizszN NGm3NZNUSU6JRWK=
LOXIMVI M135emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHKbm5KSzVyPU[xMlgzPjZizszN NH3KSo5USU6JRWK=
TGBC24TKB MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYD6THluUUN3ME22Nk4yPDlzIN88US=> NW\tWZFNW0GQR1XS
SK-MEL-2 Mk[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXYNpNKSzVyPU[zMlk5QTJizszN MUjTRW5ITVJ?
U-698-M MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fMemlEPTB;NkiuOVY5PyEQvF2= MVTTRW5ITVJ?
NCI-H1522 M3rNTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrQTWM2OD14OT6wNFQ4KM7:TR?= MYjTRW5ITVJ?
UACC-812 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGn6[WpKSzVyPU[5MlUzODlizszN NIrlOJJUSU6JRWK=
MHH-CALL-2 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXi0fIVuUUN3ME23NE4xPiEQvF2= M2iwenNCVkeHUh?=
NB5 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTPTWM2OD15MD6zOFY5KM7:TR?= Mn3BV2FPT0WU
KARPAS-299 M2S2dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jIS2lEPTB;N{CuOFQ1PyEQvF2= NFXhW5BUSU6JRWK=
NCI-H1694 NXHRUI1rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDlTWM2OD15MT6wN|Ih|ryP MXfTRW5ITVJ?
NCI-H82 NHPwUHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHxPHprUUN3ME23NU46PTB5IN88US=> NHPwd2ZUSU6JRWK=
SCC-15 Mk\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XiUmlEPTB;N{KuN|Qh|ryP NYPkNmNkW0GQR1XS
NCI-H1436 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTd{Lke0OVYh|ryP NIDYOI5USU6JRWK=
ATN-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fmV2lEPTB;N{SuOVA2KM7:TR?= M4r0[nNCVkeHUh?=
RPMI-8866 NGDVdXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTd2Lke1NFkh|ryP NG\pV3lUSU6JRWK=
HCC1599 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TIW2lEPTB;N{SuPFc{OiEQvF2= Ml75V2FPT0WU
NCI-H1155 NHHOTZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn:5TWM2OD15ND65N|Y4KM7:TR?= M37xPXNCVkeHUh?=
DOHH-2 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjHTWM2OD15ND65OVE1KM7:TR?= MUPTRW5ITVJ?
SK-NEP-1 NEjTepdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTd3LkC3OVQh|ryP NWHBZ5JzW0GQR1XS
HCC1187 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTd5Lk[xNlIh|ryP MlX6V2FPT0WU
NCI-H322M M1fW[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37xbGlEPTB;N{iuN|cxQSEQvF2= NFHRO5pUSU6JRWK=
NCI-H526 M37ISWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLoTWM2OD15OD61PFc4KM7:TR?= NWeyW49NW0GQR1XS
NCI-H2171 Mlq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;XTWM2OD15OT60NVM3KM7:TR?= NUX3XoZpW0GQR1XS
COLO-668 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlG4TWM2OD16MT61PFg1KM7:TR?= NVG1[4xoW0GQR1XS
RS4-11 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NES0d|NKSzVyPUiyMlI2ODVizszN MnezV2FPT0WU
NCI-H716 MlrMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37vSmlEPTB;OEKuPVA4PSEQvF2= MV;TRW5ITVJ?
LU-134-A M4LnNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTh|LkGzOVEh|ryP MXzTRW5ITVJ?
RPMI-8226 NH3M[VJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfIfnpKSzVyPUi0MlIyODdizszN MVTTRW5ITVJ?
KY821 MkjkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPUZnhKSzVyPUmxMlY2PTFizszN Mnr1V2FPT0WU
ECC4 NG\CTFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkK4TWM2OD17Mz64NlY6KM7:TR?= MXrTRW5ITVJ?
EW-3 MlS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3foTWlEPTB;OUSuPVA5OSEQvF2= M{f0V3NCVkeHUh?=
NB7 NVXBS2JPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2r6XmlEPTB;OUWuO|c5PiEQvF2= NW\1SXF1W0GQR1XS
NCI-H720 M1\BOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{WxbGlEPTB;OUiuOFA3OSEQvF2= MXHTRW5ITVJ?
NCI-H446 M3PLO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mof0TWM2OD17OT63OVg5KM7:TR?= M4nuXnNCVkeHUh?=
NCI-H889 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTFyND6yOFIh|ryP M3vBbXNCVkeHUh?=
EW-22 NVj6c5lUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTFyNj6xPUDPxE1? NX73WWJ2W0GQR1XS
BV-173 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXBWWN7UUN3ME2xNFgvPzJ6IN88US=> NIfte3NUSU6JRWK=
WSU-NHL NFvFfIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTFyOT62O|Eh|ryP M2DCU3NCVkeHUh?=
MN-60 NWHvXo1KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\mTWM2OD1zMEmuOlkh|ryP Ml:zV2FPT0WU
DG-75 NHP2V2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;OTWM2OD1zMUOuN|UzKM7:TR?= NUfvXIU1W0GQR1XS
DMS-79 NETodWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3rTWM2OD1zMUeuN|gzKM7:TR?= Mk\sV2FPT0WU
SK-MEL-1 NYHhV|JJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDjVFlKSzVyPUGxPE4xODlizszN NITuRmxUSU6JRWK=
DMS-153 M1fDTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTF{MT63OFUh|ryP MUXTRW5ITVJ?
NCI-H510A NF;WSIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1f4c2lEPTB;MUK3MlMzKM7:TR?= M2LTZnNCVkeHUh?=
BE-13 NEXJRopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnz3TWM2OD1zM{SuNFQ1KM7:TR?= NFTWcZNUSU6JRWK=
KP-N-YS Ml\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnnTWM2OD1zM{muO|M3KM7:TR?= MonFV2FPT0WU
SUP-T1 M4HnVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;sTWM2OD1zNEOuO|A5KM7:TR?= MlLIV2FPT0WU
EW-12 Mk\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTF2ND62PVkh|ryP NH[2bIJUSU6JRWK=
NB14 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfDTWM2OD1zNEeuNFgzKM7:TR?= MkjnV2FPT0WU
MDA-MB-134-VI M17BVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLid5RKSzVyPUG0PE4zPjhizszN Mk\DV2FPT0WU
NCI-H1770 MlvpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTERldIUUN3ME2xOVYvOjd7IN88US=> Mo[4V2FPT0WU
TUR MkfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWG5TYl{UUN3ME2xOlcvQDdizszN MYrTRW5ITVJ?
NCI-H1417 NWPpZ4JUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIqxSJVKSzVyPUG4NE4{OzFizszN M1nFe3NCVkeHUh?=
IMR-5 MnPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXZTWM2OD1zOEGuOVcyKM7:TR?= NVT3b41TW0GQR1XS
NCI-H226 NVrjOVd[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn:3TWM2OD1zOEiuPFY3KM7:TR?= M4f6bXNCVkeHUh?=
NCI-H187 M3qwNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4D3R2lEPTB;MUmwMlA3PCEQvF2= Mny3V2FPT0WU
SF539 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{T3PGlEPTB;MUmyMlczQCEQvF2= M{LxXXNCVkeHUh?=
TALL-1 NGPt[JpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUexdJh6UUN3ME2xPVgvOzB2IN88US=> MoXLV2FPT0WU
TE-441-T NV\wbJJFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPOTWM2OD1zOUmuO|M6KM7:TR?= MlX5V2FPT0WU
REH NXjtfmFNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHSd5JKSzVyPUKzOk43OjZizszN M1HpbnNCVkeHUh?=
MS-1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{f4TmlEPTB;MkO5MlEzOSEQvF2= M3vHWnNCVkeHUh?=
THP-1 M3zBPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXZNXVZUUN3ME2yOlQvPzN6IN88US=> MXvTRW5ITVJ?
NCI-H1838 M4Sxd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17MemlEPTB;MkexMlQ2PiEQvF2= NIjBc41USU6JRWK=
P30-OHK NWPCO2hCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXwb5RKSzVyPUK4N{45PDdizszN MXTTRW5ITVJ?
C8166 NEXVO4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorQTWM2OD1|NEWuN|M5KM7:TR?= M4rBc3NCVkeHUh?=

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

体内試験 Administration of MG-132 effectively rescues the expression levels and plasma membrane localization of dystrophin, β-dystroglycan, α-bdystroglycan, and α-sarcoglycan in skeletal muscle fibers from mdx mice, reduces muscle membrane damage, and ameliorates the histopathological signs of muscular dystrophy. [7] MG-132 treatment significantly reduces immobilization-induced skeletal muscle atrophy in mice, by downregulating the muscle-specific ubiquitin ligases atrogin-1/MAFbx and MuRF-1 mRNA. [8]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[1]

+ 展開

Measurement of inhibitory activities of MG-132 against 20S proteasome:

The reaction mixture for the 20S proteasome inhibitory assay contains 0.1 M Tris-acetate, pH 7.0, 20S proteasome, MG-132, and 25 μM substrate dissolved in dimethyl sulfoxide in a final volume of 1 mL. After incuba tion at 37 °C for 15 minutes, the reaction is stopped by the addition of 0.1 mL of 10% SDS and 0.9 mL of 0.1M Tris acetate, pH 9.0. The fluorescence of the reaction products is measured. To determine the IC50 against 20S proteasome, various concentrations of MG-132 are included in the assay mixture.
細胞試験:

[3]

+ 展開
  • 細胞株: KIM-2, HC11, and ES
  • 濃度: Dissolved in DMSO, final concentrations ~25 μM
  • 反応時間: 24 and 48 hours
  • 実験の流れ:

    Cells are exposed to various concentrations of MG-132 for 24, and 48 hours. Supernatant and monolayer cells are harvested by centrifugation and fixed in 70% ethanol in PBS for staining with acridine orange. Equal volumes of cells and acridine orange (5 mg/mL in PBS) are mixed on a microscope slide and examined by fluorescence microscopy. For annexin V analysis, cells are harvested by centrifugation and stained with annexin V and propidium iodide. For cell cycle analysis, cells are rehydrated in PBS at room temperature for 10 minutes, followed by staining with propidium iodide (5 mg/mL). All samples are analyzed using a Coulter Epics XL flow cytometer.


    (参考用のみ)
動物試験:

[7]

+ 展開
  • 動物モデル: Male mdx (C57BL/10ScSn DMD mdx) mice
  • 製剤: Dissolved in DMSO, and diluted in PBS
  • 投薬量: ~10 μg/kg/day
  • 投与方法: Injection
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 90 mg/mL (189.22 mM)
Ethanol 25 mg/mL (52.56 mM)
Water Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
4% DMSO+30% PEG 300+20% propylene glycol+ddH2O
混合させたのち直ちに使用することを推奨します。
2mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 475.62
化学式

C26H41N3O5

CAS No. 133407-82-6
保管
in solvent
別名 N/A

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    I want to know whether it contains EDTA or other chelating agent in this product(S2619)?

  • 回答:

    Our S2619 MG-132 doesn't contain EDTA or other chelating agent.

Proteasomeシグナル伝達経路

Proteasome Inhibitors with Unique Features

相関Proteasome製品

Tags: MG-132を買う | MG-132 ic50 | MG-132供給者 | MG-132を購入する | MG-132費用 | MG-132生産者 | オーダーMG-132 | MG-132化学構造 | MG-132分子量 | MG-132代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID